Drug intelligence / Profile preview

CD30 shRNA

Development stage: Preclinical
Lead developer: Nanfang Hospital, Southern Medical University
Modality: Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intratumoral

Overview

CD30 shRNA is a short hairpin RNA (shRNA) designed to silence the expression of the CD30 (TNFRSF8) gene. In the context of activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL), CD30 shRNA is used to knock down CD30 expression, which has been shown to inhibit cell proliferation and division by downregulating the ERK 1/2 and p38 MAPK signaling pathways. This research suggests that targeting CD30 via RNA interference could be a potential therapeutic strategy for DLBCL.

Other names: CD30 short hairpin RNACD-30 short hairpin RNACD 30 short hairpin RNA

Targets

CD30 (CD30 antigen)

Beyond the preview

Go deeper on CD30 shRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD30 shRNA.

Explore the full profile